Bayer to invest $150m in cell culture technology facility in Berkeley

Article views

2543

VIEWS

Bayer has announced its intention to invest $150m
in the construction of a cell culture technology facility at its pharmaceutical
development and manufacturing site in Berkeley, California.

The Cell Center Technology Center will
support Bayer's biologics portfolio and aim to accelerate the development of
biological therapies. Built on Bayer's Berkeley campus, the 40,000 square
foot facility, has been scheduled to begin clinical production in late-2021 and
will have an emphasis on oncology, cardiology and additional specialty care
therapeutic areas.

"We are especially proud to bring this
investment to Berkeley, where Bayer has been for many years, and to the
greater San Francisco Bay Area, the birthplace of biotechnology and a
global epicenter of drug development innovation."

Bayer has partnered with both Fluor and GE
Healthcare on the Cell Culture Technology Center and will tap into their
expertise in designing flexible and scalable facilities. GE Healthcare's FlexFactory
technology platform is set to be integrated at the facility.

Judy Chou, senior vice-president and global
head of Bayer Biotech, remarked: "Bayer's Cell Center Technology Center
will combine automation, digital capabilities and single-use bioprocessing
technologies to streamline production to allow us to bring new medicines to
patients faster."

Download your free copy of DATAx Guide to Gaming Analytics

Read about the latest technological developments and data trends transforming the world of gaming analytics in this exclusive ebook from the DATAx team.